On 13 April 2017, Roche entered a licensing agreement with Bristol Myers Squibb (BMS) for the license of the anti-myostatin adnectin BMS-986089.
The agreement meant Roche would pay BMS an upfront payment of $170 million with the potential of milestone payment of $205 million. Biogen have also entered a licensing agreement with BMS for the anti-eTau compound which is phase II ready for potential in Alzheimer’s Disease and progressive supranuclear palsy (PSP). Licensing assets to both Biogen and Roche means that BMS will be able to prioritise other potential opportunities for asset development for their portfolio.
Figure 1 shows a comparable number between licensing and partnership deals within Duchenne Muscular Dystrophy.
However, figure 2 shows over the last five years a growth in the number of licensing deals occurring in the Duchenne Muscular Dystrophy space year by year meaning this is a strong area providing companies with opportunities for asset development for the future.
Related Companies
